Abstract:Objective:To compare the prognosis of mildly or severely symptomatic patients with obstructive hypertrophic cardiomyopathy (OHCM) who underwent alcohol septal ablation (ASA).Methods:This retrospective study cohort consisted of patients with OHCM who received ASA treatment in Beijing Anzhen Hospital, Capital Medical University from March 2001 to August 2021. These patients were divided into mildly and severely symptomatic groups according to the severity of clinical symptoms. Long-term follow-up was conducted, and the following data were collected: duration of follow-up, postoperatire treatment, New York Heart Association (NYHA) classification, arrhythmia events and pacemaker implantation, echocardiographic parameters, and cause of death. Overall survival and survival free from OHCM-related death were observed, and the improvement of clinical symptoms and resting left ventricular outflow tract gradient (LVOTG) and the incidence of new-onset atrial fibrillation were evaluated. The Kaplan-Meier method and log-rank test were used to determine and compare the cumulative survival rates of the different groups. Cox regression analysis models were used to determine predictors of clinical events.Results:A total of 189 OHCM patients were included in this study, including 68 in the mildly symptomatic group and 121 in the severely symptomatic group. The median follow-up of the study was 6.0 (2.7, 10.6) years. There was no statistical difference in overall survival between the mildly symptomatic group (5-year and 10-year overall survival were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year overall survival were 94.2% and 83.9%, respectively, P=0.405); there was also no statistical difference in survival free from OHCM-related death between the mildly symptomatic group (5-year and 10-year survival free from HCM-related death were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year survival free from HCM-related death were 95.2% and 92.6%, respectively, P=0.846). In the mildly symptomatic group, NYHA classification was improved after ASA ( P<0.001), among which 37 patients (54.4%) were in NYHA class Ⅰ, and the resting left ventricular outflow tract gradient (LVOTG) decreased from 67.6 (42.7, 90.1) mmHg (1 mmHg=0.133 kPa) to 24.4 (11.7, 35.6) mmHg ( P<0.001). In severely symptomatic group, NYHA classification was also improved post ASA ( P<0.001), among which 96 patients (79.3%) improved by at least one NYHA classification, and the resting LVOTG decreased from 69.6 (38.4, 96.1) mmHg to 19.0 (10.6, 39.8) mmHg ( P<0.001). The incidence of new-onset atrial fibrillation was similar between the mildly and severely symptomatic groups (10.2% vs. 13.3%, P=0.565). Cox multivariate regression analysis showed that age was an independent predictor of all-cause mortality in OHCM patients post ASA ( HR=1.068, 95% CI 1.002-1.139, P=0.042). Conclusions:Among patients with OHCM treated with ASA, overall survival and survival free from HCM-related death were similar between mildly symptomatic group and severely symptomatic group. ASA therapy can effectively relieve resting LVOTG and improve clinical symptoms in mildly or severely symptomatic patients with OHCM. Age was an independent predictor of all-cause mortality in OHCM patients post ASA.

Hypertrophic cardiomyopathy with latent obstruction: Clinical characteristics and surgical results

Selective Interventricular Septal Radiofrequency Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?

Prevalence and clinical impact of latent obstruction in hypertrophic cardiomyopathy

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and Three-Year Noninvasive Follow-Up in 18 Patients.

Hypertrophic Cardiomyopathy With Elongated Mitral Valve Leaflets: Clinical Characteristics and Surgical Results

Hypertrophic obstructive cardiomyopathy with a basal septal thickness of 16 mm or less: clinical characteristics and surgical results

Characteristics And Surgical Results Of Patients With Hypertrophic Obstructive Cardiomyopathy Without Intrinsic Mitral Valve Diseases Undergoing Mitral Subvalvular Procedures During Myectomy

Efficacy of Alcohol Septal Ablation in Mildly Symptomatic or Severely Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Influence of percutaneous transluminal septal myocardial ablation of hypertrophic obstructive cardiomyopathy on mitral regurgitation

Myectomy with and without Mitral Subvalvular Repair in Patients with Hypertrophic Obstructive Cardiomyopathy with Grade 3 to 4+Mitral Regurgitation without Intrinsic Mitral Valve Disease: A Retrospective Observational Study

Contemporary Surgical Management of Hypertrophic Cardiomyopathy

Application of special surgical instruments in transaortic septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy

Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment

Enlargement of Left Ventricular Outflow Tract Using an Autologous Pericardial Patch for the Anterior Mitral Valve Leaflet and Septal Myectomy Through Trans-mitral Approach for the Treatment of Hypertrophic Obstructive Cardiomyopathy

Surgical Treatment on Congenital Heart Disease with Severe Pulmonary Hypertension

Mini-invasive Surgical Instruments in Transaortic Myectomy for Hypertrophic Obstructive Cardiomyopathy: a Single-Center Experience with 168 Cases

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction

Clinical Effect of the Modified Morrow Septal Myectomy Procedure for Biventricular Hypertrophic Cardiomyopathy

Obstruction of Left Ventricular Outflow Tract after Mechanical Mitral Valve Replacement.

Transapical beating-heart septal myectomy for recurrent left ventricular outflow tract obstruction after septal reduction therapy in hypertrophic obstructive cardiomyopathy

Left Ventricular Outflow Tract Gradient Provoked by Upright Position or Exercise in Treated Patients with Hypertrophic Cardiomyopathy without Obstruction at Rest